Touro Scholar
NYMC Faculty Publications

Faculty

8-25-2016

Colorectal Cancer on the Decline
Albert B. Lowenfels
New York Medical College

Patrick Maisonneuve
Ravinder Mamtani
New York Medical College

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs
Part of the Oncology Commons

Recommended Citation
Lowenfels, A. B., Maisonneuve, P., & Mamtani, R. (2016). Colorectal cancer on the decline. The New
England Journal of Medicine, 375(8), 803. doi:10.1056/NEJMc1608037#SA1

This Letter to the Editor is brought to you for free and open access by the Faculty at Touro Scholar. It has been
accepted for inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more
information, please contact touro.scholar@touro.edu.

Correspondence

less likely to have a response to the drug or survive to hospital discharge. We agree that earlier
use of antiarrhythmic drugs provides a greater
potential for clinical benefit that may be lost if
the drugs are administered late. For example, in
prespecified subgroup analyses in our trial, we
observed no effect (neither benefit nor harm)
from active drug among 839 patients with unwitnessed out-of-hospital cardiac arrest; these patients typically have a more prolonged duration
between arrest and treatment than do patients
with witnessed out-of-hospital arrest. Conversely,
among 1934 patients with out-of-hospital cardiac
arrest that was witnessed by a bystander, the rate
of survival to hospital discharge was significantly
increased by an absolute margin of 5 percentage
points with active drug as compared with placebo
(P≤0.04). Furthermore, among 154 patients in
whom out-of-hospital cardiac arrest was witnessed
by EMS and cardiopulmonary resuscitation, shock,
and the study drug were administered soon after
the arrest, the absolute increase in survival to
hospital discharge with amiodarone as compared
with placebo was 21.9 percentage points (P<0.01).
These findings suggest a pronounced drug effect
in patients who are in an earlier, more responsive
stage of cardiac arrest. The overall results of the
trial are arguably best interpreted in the context
of this group of patients.4
Much remains to be learned about the effec-

tiveness of pharmacologic therapies in patients
with out-of-hospital cardiac arrest. We think
that our trial has advanced the knowledge and
understanding of these therapies and has provided reasons to be optimistic about their use in
shock-refractory cardiac arrest.
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Colorectal Cancer on the Decline
To the Editor: In their Perspective article, Welch Albert B. Lowenfels, M.D.
and Robertson (April 28 issue)1 provide evidence New York Medical College
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To the Editor: Welch and Robertson suggest
that screening cannot explain the entire decline
in colorectal-cancer incidence and mortality (i.e.,
overall decreases of 40% and 50%, respectively,
among adults in the United States) in the period
from 1975 to 2012 and that other factors (e.g.,
risk factors such as diet, lifestyle, and drugs)
must be involved. Surprisingly, the authors did
not cite the respective proportions of the decline
that were attributable to screening as opposed to
those other factors, as analyzed in the “Annual
Report to the Nation on the Status of Cancer,
1975–2006,” which features colorectal-cancer
trends and the effect of risk factors, screening,
and treatment.1 Using the well-validated Microsimulation Screening Analysis (MISCAN)–Colon
model,2 the authors of that report concluded that
53% of the overall observed decline in colorectalcancer–related mortality could be explained by
screening, as compared with 35% that could be
explained by changes in risk factors and 12%
by treatment.1 The same MISCAN-Colon model
allowed analysts to suggest that differences in
screening accounted for 42% and 19% of the observed disparities in colorectal-cancer incidence
and mortality, respectively, between blacks and
whites in the United States.3
Claude Matuchansky, M.D.
Paris–Diderot University
Paris, France
claude.matuchansky@wanadoo.fr
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The authors reply: Although we are aware of
the data cited by Lowenfels et al., we believe they
must be kept in proper context. The incidence of
colorectal cancer is rising in the population
younger than 50 years of age, but the absolute
increase is small: approximately 2 cases per
100,000 persons. The corresponding decrease in
the population 50 years of age or older, by contrast,
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is approximately 100 cases per 100,000 persons.1
Despite these opposing trends, the incidence of
colon cancer remains 15 times as high in the
older group as in the younger group. Given the
low absolute risk and stable mortality among
young people, as well as the fact that their disease may have distinct biologic factors2 that make
it less amenable to early detection, we believe it
would be a mistake to extend screening on the
basis of these trends.
We are also aware of the microsimulation
modeling cited by Matuchansky. We worry, as
others do,3 that although the output of statistical
models have the appeal of quantitative precision,
their precision may be more apparent than real.
Modeling is only as good as its data inputs and
often rests on unverifiable assumptions regarding factors such as the rates at which polyps
transition to cancer and at which cancers transition from early to later stages.
The suggestion that 53% of the decline is due
to screening overstates the precision of the estimate. We believe that it also overstates the magnitude of the likely effect of screening. As the
figure in our article shows, since 1975, colorectalcancer–related mortality has fallen from approximately 100 cases per 100,000 persons to 45 cases
per 100,000, and 80% of that decline occurred
before 2005 — the first year that 50% of the
population was screened. How can more than
half the decline in mortality be attributed to
screening when more than half the decline
occurred before even half the population was
exposed to screening?
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